This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuriyama, M. Articles by Chu, T. M. Search for Related Content PubMed PubMed Citation Articles by Kuriyama, M. Articles by Chu, T. M.

Quantitation of Prostate-specific Antigen in Serum by a Sensitive Enzyme Immunoassay¹

Department of Diagnostic Immunology Research and Biochemistry, Roswell Park Memorial Institute, Buffalo, New York 14263 [M. K., M. C. W., L. D. P., C. S. K., T. S., L. V., G. P. M., T. M. C.], and Department of Urology, Gifu University School of Medicine, Gifu, 500, Japan [T. N.]

A sensitive sandwich-type enzyme immunoassay has been developed for quantitation of a human prostate-specific antigen (PA). With this method, PA at a concentration as low as 0.10 ng/ml can be detected. The assay was reproducible as within and between assays yielded a coefficient of variation of 5.7% and 4.6%, respectively. Only human prostate tissues (n = 31) were shown to contain PA. No PA was detected in other human normal or tumor tissues (n = 13). PA was not detectable in sera from normal females (n = 17) or female cancer patients (n = 25). A mean ± S.D. of 0.47 ± 0.661 ng/ml (ranging from less than 0.10 to 2.6) was obtained from a group of 51 normal males. Sera from male patients with nonprostatic cancer contained a similar range of PA as that of normal males. Patients with prostate cancer (371 of 442) and benign prostatic hypertrophy (13 of 19) were shown to have elevated levels of circulating PA. Although no quantitative difference in PA levels was found between the benign prostatic hypertrophy group and Stage A of prostatic cancer, patients with Stages C and D prostatic cancer exhibited significantly elevated levels of PA qualitatively and quantitatively. These results therefore indicate that PA is a histiotypic product of the prostate and may be of use as an adjunctive tool in diagnostic procedures of prostate cancer.

¹ This work was supported in part by Research Grant CA-15437 awarded by the National Cancer Institute, Department of Health, Education and Welfare.

² On leave from the Department of Urology, Gifu University School of Medicine, Gifu, Japan.

³ To whom requests for reprints should be addressed.

Received 5/ 2/80. Accepted 9/15/80.

This article has been cited by other articles:

				M. Ishibashi Standardization of Prostate-Specific Antigen (PSA) Assays: Can Interchangeability of PSA Measurements Be Improved? Clin. Chem., January 1, 2006; 52(1): 1 - 2. [Full Text] [PDF]

				I. M. Thompson, D. K. Pauler, P. J. Goodman, C. M. Tangen, M. S. Lucia, H. L. Parnes, L. M. Minasian, L. G. Ford, S. M. Lippman, E. D. Crawford, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level <=4.0 ng per Milliliter N. Engl. J. Med., May 27, 2004; 350(22): 2239 - 2246. [Abstract] [Full Text] [PDF]

				S. Oottamasathien and E. D. Crawford Should Routine Screening for Prostate-Specific Antigen Be Recommended? Arch Intern Med, March 24, 2003; 163(6): 661 - 663. [Full Text] [PDF]

				K. Mistry and G. Cable Meta-Analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate Carcinoma J Am Board Fam Med, March 1, 2003; 16(2): 95 - 101. [Abstract] [Full Text] [PDF]